536 related articles for article (PubMed ID: 24071646)
21. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
[TBL] [Abstract][Full Text] [Related]
22. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract][Full Text] [Related]
23. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
Jiang Y; Yuan Q; Fang Q
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1087-95. PubMed ID: 24728492
[TBL] [Abstract][Full Text] [Related]
24. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
26. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
[TBL] [Abstract][Full Text] [Related]
27. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Han SY; Zhao MB; Zhuang GB; Li PP
Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
[TBL] [Abstract][Full Text] [Related]
28. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
29. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
30. 3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.
Sheng Y; Li W; Zhu F; Liu K; Chen H; Yao K; Reddy K; Lim DY; Oi N; Li H; Peng C; Ma WY; Bode AM; Dong Z; Dong Z
J Biol Chem; 2014 Oct; 289(41):28192-201. PubMed ID: 25122774
[TBL] [Abstract][Full Text] [Related]
31. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
[TBL] [Abstract][Full Text] [Related]
32. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Venkatesha VA; Joshi A; Venkataraman M; Sonawane V; Bhatia D; Tannu P; Bose J; Choudhari S; Srivastava A; Pandey PK; Lad VJ; Sangana R; Ahmed T; Damre A; Deore V; Sahu B; Kumar S; Sharma S; Agarwal VR
Mol Cancer; 2014 Dec; 13():259. PubMed ID: 25466244
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
[TBL] [Abstract][Full Text] [Related]
34. The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
Wang J; Wei H; Zhao B; Li M; Lv W; Lv L; Song B; Lv S
J Mol Histol; 2014 Dec; 45(6):641-52. PubMed ID: 25008024
[TBL] [Abstract][Full Text] [Related]
35. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
[TBL] [Abstract][Full Text] [Related]
36. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
[TBL] [Abstract][Full Text] [Related]
37. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
Janmaat ML; Rodriguez JA; Gallegos-Ruiz M; Kruyt FA; Giaccone G
Int J Cancer; 2006 Jan; 118(1):209-14. PubMed ID: 16003751
[TBL] [Abstract][Full Text] [Related]
38. Amplification of Wild-type
Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
[TBL] [Abstract][Full Text] [Related]
39. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
40. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
